{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"The proportion of participants who reported discontinuing treatment due to a treatment-related toxicity will be reported.","groups":[{"description":"Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months","title":"Proportion of Participants Discontinuing Treatment Due to Toxicity","type":"SECONDARY","unitOfMeasure":"proportion of participants"}